{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:29:40Z","timestamp":1791764980901,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022084","name":"Peter MacCallum Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022084","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euf.2025.11.016","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T12:25:11Z","timestamp":1765023911000},"page":"24-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neoadjuvant Systemic Therapy in High-risk Localised Prostate Cancer: Current Evidence and Future Directions"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6234-3522","authenticated-orcid":false,"given":"Abdullah","family":"Al-Khanaty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hennes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon L.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-6234","authenticated-orcid":false,"given":"Renu S.","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.11.016_b0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2025.11.016_b0010","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer","volume":"18","author":"Devos","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2025.11.016_b0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/cancers17010099","article-title":"Current status of neoadjuvant treatment before surgery in high-risk localized prostate cancer","volume":"17","author":"G\u00f3mez Rivas","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.euf.2025.11.016_b0020","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.11.016_b0025","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.11.016_b0030","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cncr.35170","volume":"130","author":"McKay","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.11.016_b0035","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1158\/1078-0432.CCR-23-0731","article-title":"Neoadjuvant cabazitaxel plus abiraterone\/leuprolide acetate in patients with high-risk prostate cancer: ACDC-RP phase II trial","volume":"29","author":"Fleshner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2025.11.016_b0040","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/pros.24118","article-title":"Targeting backdoor androgen synthesis through AKR1C3 inhibition: a presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer","volume":"81","author":"Graham","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2025.11.016_b0045","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.11.016_b0050","unstructured":"Janssen Research & Development, LLC. A study of apalutamide in participants with high-risk, localized or locally advanced prostate cancer who are candidates for radical prostatectomy (PROTEUS). https:\/\/clinicaltrials.gov\/study\/NCT03767244."},{"key":"10.1016\/j.euf.2025.11.016_b0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","article-title":"Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: a single-arm phase 1 trial","volume":"6","author":"Golan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.11.016_b0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.11.016_b0065","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41585-024-00913-8","article-title":"Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer","volume":"21","author":"Eapen","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2025.11.016_b0070","unstructured":"University of British Columbia. The Genomic Umbrella Neoadjuvant Study (GUNS). https:\/\/clinicaltrials.gov\/study\/NCT04812366."},{"key":"10.1016\/j.euf.2025.11.016_b0075","unstructured":"McKay R. Study of neoadyuvant PARP inhibition followed by radical prostatectomy in patients with unfavorable intermediate- risk or high-risk prostate cancer with BRCA 1\u20442 gene alterations (NePtune). https:\/\/clinicaltrials.gov\/study\/NCT05498272."}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:03:54Z","timestamp":1773871434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925003499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2405456925003499"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.11.016","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Systemic Therapy in High-risk Localised Prostate Cancer: Current Evidence and Future Directions","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}